A 60-year-old female underwent total tumor resection of a right frontal lobe meningioma which located on the convexity of the brain in September 2018, and the pathological diagnosis was atypical meningioma. In October 2021, the patient was admitted to the hospital with cough and shortness of breath. A computed tomography (CT) scan revealed the presence of large masses in the right thoracic and abdominal cavity and no recurrence was found in craniocerebral magnetic resonance imaging (MRI). The histological features of the lung tumor were similar to that of the brain mass, and the tumor cells were positive for vimentin, EMA, and Ki-67, and negative for TTF1, PD-L1, P40, and chromogranin. Based on these biopsy and immunohistochemistry (IHC) findings, the masses were identified as metastatic meningiomas. The patient was treated with the anti-PD-1 agent camrelizumab (200 mg, Day 1) combined with the anti-VEGF agent anlotinib (10 mg, Days 1–14) every 3 weeks without radiation treatment. After two cycles of this regimen, the patient’s symptoms were completely resolved without no other adverse events, and CT revealed that the tumor had shrunk significantly by > 80%. Biopsy performed after the two cycles of treatment and immunohistochemistry analysis revealed that infiltration of CD4+ T lymphocyte, CD8+ T lymphocyte, and CD68+ macrophage in the tumor microenvironment was significantly increased compared with that before treatment. The number of peripheral blood CD4+T lymphocyte and CD8+T lymphocyte continued to increase as the tumor shrank. These findings indicate that combined anti-PD-1 and anti-VEGF treatment stimulates peripheral blood immune cells to kill metastatic meningioma cells. The patient has been given eleven cycles of the treatment every 3 weeks from October 21, 2021 to June 21, 2022 without tumor progression.